

Emily Feneberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/433299/publications.pdf>

Version: 2024-02-01

26
papers

1,321
citations

516561

16
h-index

454834

30
g-index

31
all docs

31
docs citations

31
times ranked

1969
citing authors

#	ARTICLE	IF	CITATIONS
1	Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnp-2015-311387.	0.9	207
2	Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 157-164.	0.9	174
3	Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology, 2018, 90, e22-e30.	1.5	148
4	Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 351-356.	1.1	131
5	Towards a TDP-43-Based Biomarker for ALS and FTLD. Molecular Neurobiology, 2018, 55, 7789-7801.	1.9	100
6	Poly(ubiquitin) in cerebrospinal fluid links C9orf72-associated dipeptide repeat expression to the asymptomatic phase of ALS/FTD. EMBO Molecular Medicine, 2017, 9, 859-868.	3.3	90
7	Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 239-247.	0.9	89
8	Intact Protein Analysis of Ubiquitin in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Differences in Alzheimer's Disease and Frontotemporal Lobar Degeneration. Journal of Proteome Research, 2014, 13, 4518-4525.	1.8	41
9	Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 68-74.	0.9	39
10	Amyotrophic lateral sclerosis: the complex path to precision medicine. Journal of Neurology, 2018, 265, 2454-2462.	1.8	36
11	An ALS-linked mutation in TDP-43 disrupts normal protein interactions in the motor neuron response to oxidative stress. Neurobiology of Disease, 2020, 144, 105050.	2.1	30
12	Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain. Brain Communications, 2022, 4, fcac029.	1.5	29
13	Neurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an update. Journal of Neurochemistry, 2016, 138, 184-192.	2.1	26
14	Progranulin as a candidate biomarker for therapeutic trial in patients with ALS and FTLD. Journal of Neural Transmission, 2016, 123, 289-296.	1.4	26
15	Detection and quantification of novel C-terminal TDP-43 fragments in ALS-TDP. Brain Pathology, 2021, 31, e12923.	2.1	26
16	Cerebrospinal fluid proteomics and protein biomarkers in frontotemporal lobar degeneration: Current status and future perspectives. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2015, 1854, 757-768.	1.1	21
17	SARS-CoV-2 and neurodegenerative diseases: what we know and what we don't. Journal of Neural Transmission, 2022, 129, 1155-1167.	1.4	19
18	Initial Identification of a Blood-Based Chromosome Conformation Signature for Aiding in the Diagnosis of Amyotrophic Lateral Sclerosis. EBioMedicine, 2018, 33, 169-184.	2.7	17

#	ARTICLE	IF	CITATIONS
19	Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 276-286.	1.1	14
20	Elevated glial fibrillary acidic protein levels in the cerebrospinal fluid of patients with narcolepsy. <i>Sleep Medicine</i> , 2013, 14, 692-694.	0.8	13
21	Influence of the blood-CSF-barrier function on S100B in neurodegenerative diseases. <i>Acta Neurologica Scandinavica</i> , 2013, 128, 249-256.	1.0	9
22	Amyotrophic lateral sclerosis with a heterozygous D91A SOD1 variant and classical ALS-TDP neuropathology. <i>Neurology</i> , 2020, 95, 595-596.	1.5	9
23	Hibernation Impairs Odor Discrimination – Implications for Alzheimer’s Disease. <i>Frontiers in Neuroanatomy</i> , 2019, 13, 69.	0.9	5
24	Advancing mechanistic understanding and biomarker development in amyotrophic lateral sclerosis. <i>Expert Review of Proteomics</i> , 2021, 18, 977-994.	1.3	5
25	Recent biomarker approaches in the diagnosis of frontotemporal lobar degeneration/Neurochemische Ansätze in der Diagnose der Frontotemporalen Lobärdegeneration. <i>Laboratoriums Medizin</i> , 2012, 36, .	0.1	1
26	Prolactin Serum Concentrations After Electroconvulsive Therapy in a Depressed Patient With Cabergoline-Treated Prolactinoma. <i>Journal of ECT</i> , 2015, 31, e28-e29.	0.3	0